Login
Companies $PVLA
$144.90 +$0.30 (0.21%) After hours
PALVELLA THERAPEUTICS, INC. logo

PALVELLA THERAPEUTICS, INC.

palvellatx.com

What Do They Do?

Develops topical drug candidates for patients with serious, rare skin diseases and vascular malformations.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −117% (Loss)
vs −$11.3M in Q3 FY2025
  • Aug 4, 2026 Submitted the first module of a rolling NDA for QTORIN rapamycin Full submission is on track for the second half of 2026; a standalone U.S. launch is planned for the first half of 2027, if approved.

From Anticalin to QTORIN The older report centered on Anticalin protein drugs for respiratory and cancer-related conditions, with several programs developed alongside pharmaceutical partners. The latest report instead focuses on topical QTORIN candidates for rare skin diseases and vascular malformations, with plans to develop and, if approved, commercialize them.

Who Do They Compete With?

Competes with Kaken Pharmaceutical, Nobelpharma, Novartis Pharmaceuticals, Protara Therapeutics, Relay Therapeutics, Vaderis Therapeutics, and Quoin Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support